Travere Therapeutics Inc (Travere Therapeutics) is an integrated biopharmaceutical company that develops and commercializes therapies for rare diseases with unmet medical needs. The company’s marketed products include Chenodal, Cholbam, and Thiola. Thiola is used in combination with high fluid intake to help prevent the formation of one type (cystine) of kidney stone in certain adult and pediatric patients. Its pipeline portfolio encompasses three clinical-stage candidates: Sparsentan (RE-021); CDCA; Pegtibatinase (TVT-058); and a pre-clinical discovery program. Sparsentan is an approved therapeutic agent that is not only a potential angiotensin receptor blocker (ARB), but also a selective endothelin receptor antagonist (ERA) with in vitro selectivity toward endothelin receptor type A.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company conducts research to develop therapeutics for rare and genetic diseases with unmet clinical needs of focal segmental glomerulosclerosis; pantothenate kinase-associated neurodegeneration (PKAN); and for primary biliary cholangitis (PBC). It also participates in pre-clinical discovery program targeted at the treatment of ALGS deficiency. In FY2022, the company spent US$229.5 million on its R&D activities. The first patent family consists of patents and patent applications covering methods of using Sparsentan in the treatment of various kidney diseases, including focal segmental glomerulosclerosis (FSGS) and IgAN, by achieving a specified urine protein to creatinine ratio. As of December 31, 2022, Travere Therapeutics' first patent family comprised US patent and pending US patent application, and a European patent, a Chinese patent, and corresponding foreign patent applications pending in US, Australia, Brazil, Canada, China, Japan, Korea, the European Patent Office, Hong Kong, New Zealand and South Africa. Travere Therapeutics' second patent family covers the methods of using sparsentan for treating Alport syndrome. As of December 31, 2022, Travere Therapeutics' second patent family comprised of a pending patent application in US, Australia Brazil, Canada, Israel, Japan, Korea, Mexico, China, the European Patent Office, Hong Kong, New Zealand and South Africa. Its third patent family is directed to an amorphous form of sparsentan. As of December 31, 2022, Travere Therapeutics' third patent family comprised an international patent application. The fourth patent family is comprised of a pending international patent application for treating of kidney diseases or disorders. The fifth patent family is comprised of a U.S. provisional patent application.